Alendronate Sodium: Uses, Dosing Rules, and Long-Term Risks

Alendronate sodium is one of the most widely prescribed medications for osteoporosis, belonging to a class of drugs called bisphosphonates that slow the breakdown of bone. First synthesized in the 1970s and later reformulated as a sodium salt tablet by Merck’s pharmaceutical chemists, it remains a first-line treatment for postmenopausal osteoporosis, male osteoporosis, and bone loss caused by long-term steroid use. Its effectiveness is well established across large trials, but the drug comes with famously strict dosing instructions and a handful of rare but serious long-term risks that are worth understanding.

How Alendronate Works Inside Bone

Bone is constantly being remodeled. Specialized cells called osteoclasts dissolve old bone, while osteoblasts build new bone to replace it. In osteoporosis, the balance tips toward too much breakdown. Alendronate works by binding tightly to hydroxyapatite, the mineral that makes up most of your bone’s hard structure, and then getting absorbed by osteoclasts when they start dissolving that section of bone. Once inside the osteoclast, alendronate disrupts the cell’s internal chemistry, ultimately killing it. Fewer active osteoclasts means less bone is broken down, and the balance shifts back toward preservation.

What sets alendronate apart from some other bisphosphonates is how strongly it grips onto bone mineral. Laboratory studies measuring how bisphosphonates bind to hydroxyapatite have consistently found that alendronate ranks among the strongest binders, alongside zoledronate, while drugs like risedronate and etidronate bind more loosely.¹ Molecular dynamics simulations have confirmed this ranking, showing alendronate at or near the top for binding free energy to the hydroxyapatite surface.² This strong binding is clinically relevant because it means alendronate stays embedded in bone for a long time, continuing to be picked up by osteoclasts even after you stop taking the drug. That long persistence is what eventually makes “drug holidays” feasible.

Why the Dosing Instructions Are So Particular

If you have ever been prescribed alendronate, you probably remember the unusually specific instructions: take it first thing in the morning on an empty stomach, with a full glass of plain water, then stay upright and eat nothing for at least 30 minutes. These are not arbitrary precautions. They exist because almost none of the drug you swallow actually makes it into your bloodstream.

In clinical studies, alendronate’s oral bioavailability averaged less than 1% when taken correctly with water on an empty stomach, followed by fasting for two hours afterward.³ That already tiny absorption gets dramatically worse with food. Waiting only 30 minutes instead of two hours before eating reduced absorption by about 40%. Taking the tablet with breakfast or two hours after eating cut absorption by more than 85%. Even coffee or orange juice taken at the same time as the pill reduced bioavailability by roughly 60%.⁴ The drug has a very short absorption window in the upper small intestine, and food ingredients bind to it readily, preventing absorption.⁵

The instruction to remain upright and drink a full glass of water addresses a different concern: esophageal irritation. Early reports after the drug’s approval found that esophagitis tended to occur in people who swallowed the tablet with little water, lay down during or after taking it, or continued using the drug despite developing symptoms. Preexisting esophageal conditions also raised the risk.⁶ The weekly 70 mg formulation, which most people take today instead of the daily 10 mg pill, reduces the number of times the esophagus is exposed to the drug and has made this less of a concern in practice.

Fracture Prevention in Postmenopausal Women

The evidence base for alendronate in postmenopausal osteoporosis comes from some of the largest bone-drug trials ever conducted. In the Fracture Intervention Trial, which enrolled thousands of postmenopausal women, alendronate reduced the risk of radiographic vertebral fractures by about 44% overall.⁷ For women who already had osteoporosis-range bone density at the hip, clinical fractures dropped by 36%. However, in women with low bone density that had not yet crossed the osteoporosis threshold, there was no significant reduction in clinical fractures.⁸

When results from both arms of the Fracture Intervention Trial were pooled to get a clearer picture in women with osteoporosis, the drug cut hip fracture risk by roughly half, vertebral fracture risk by close to half, and overall clinical fracture risk by about 30%. The reduction in clinical fractures became statistically significant within the first year of treatment.⁹ These findings established alendronate as a reliable fracture-prevention tool for postmenopausal women who have true osteoporosis, while also making clear that the benefit is less convincing for women with only mildly reduced bone density.

Efficacy in Men and Steroid-Induced Bone Loss

Osteoporosis is often framed as a women’s disease, but men account for a substantial share of fractures in older age. In a trial of men with primary osteoporosis, alendronate increased bone density at the lumbar spine by about 7% over two years, compared to under 2% with placebo. Vertebral fracture rates were dramatically different: under 1% in the alendronate group versus 7% in the placebo group. Men taking the drug also lost less height over the study period.¹⁰

Alendronate has also been studied in people taking long-term corticosteroids, which are notorious for causing rapid bone loss. In a trial of patients on steroids, those given 10 mg daily of alendronate saw spine bone density increase by about 3%, while the placebo group actually lost bone. Hip density followed a similar pattern, with alendronate users gaining and placebo users losing.¹¹ Taken together, these trials confirmed that alendronate works across a broad range of osteoporosis types, not just the postmenopausal form.¹²

Paget’s Disease of Bone

Beyond osteoporosis, alendronate is approved for Paget’s disease, a condition where localized patches of bone are broken down and rebuilt too quickly, resulting in enlarged, weakened, and sometimes painful bones. Treatment is given at 40 mg daily for six months, a higher dose than the osteoporosis regimen. In clinical trials, alendronate reduced serum alkaline phosphatase, the main blood marker of Paget’s disease activity, by more than 70%. More than three-quarters of treated patients achieved a meaningful response, compared to fewer than a third on the older drug etidronate and none on placebo.¹³ The drug also improved radiologic findings and reduced markers of bone resorption, outperforming etidronate and calcitonin, which typically brought alkaline phosphatase down by only 40 to 50%.¹⁴

Dosing matters here. An earlier trial comparing 20 mg and 40 mg daily found that the lower dose was insufficient for Paget’s disease, with no patient achieving disease remission, while 40 mg worked but carried a higher rate of side effects.¹⁵ This illustrates a general principle with alendronate: the drug’s effects are dose-dependent and cannot be compensated for by simply extending the treatment period at a lower dose.

Atypical Femur Fractures and Long-Term Use

The most discussed long-term risk of alendronate is atypical femoral fracture, a specific type of break that occurs along the shaft of the thigh bone rather than at the hip joint. These fractures are thought to result from excessive suppression of bone turnover: when new bone stops replacing old bone altogether, microdamage can accumulate in areas of high stress until the bone snaps, sometimes with little or no trauma.

A meta-analysis found that short-term use of alendronate did not increase the risk of these fractures, but use beyond five years did.¹⁶ However, the picture is not as alarming as some media coverage has suggested. A large nationwide cohort study from Denmark found that long-term users of ten or more years did not have a significantly increased risk of these fractures overall, and the ratio of atypical to typical hip fractures was similar in alendronate users and non-users.¹⁷ A separate register-based study found that patients who stuck closely to their alendronate regimen actually had a lower risk of subtrochanteric fractures than less adherent users, and that these fractures behaved epidemiologically like typical osteoporotic fractures.¹⁸

The takeaway is that atypical femoral fractures are real but rare, and the risk needs to be weighed against the well-documented fracture prevention benefits. For most patients, the fractures alendronate prevents far outnumber the atypical fractures it might contribute to.

Jaw Osteonecrosis

Osteonecrosis of the jaw, where a section of jawbone dies and becomes exposed, is the other rare adverse event linked to bisphosphonates. It occurs far more commonly with the high-dose intravenous bisphosphonates used in cancer treatment than with oral osteoporosis doses, but it does occur with alendronate at low rates. A Danish study of over 60,000 alendronate users found that recent use was associated with about a fourfold increase in risk of surgically treated jaw osteonecrosis compared to past use, and long-term use beyond five years roughly doubled the risk. Rheumatoid conditions and proton pump inhibitor use independently raised the odds as well.¹⁹

Tooth extraction appears to be a major trigger. A study of osteoporotic patients found that dental extraction was the strongest independent predictor of jaw osteonecrosis, raising the odds nearly tenfold. Alendronate use beyond three years and having rheumatoid arthritis were also independent risk factors.²⁰ This is why your dentist will ask about bisphosphonate use before performing extractions or other invasive dental procedures. It does not mean the drug should be avoided, but it does mean dental health should be well maintained while you are on it.

Drug Holidays

Because alendronate embeds itself in bone and continues working after you stop taking it, many clinicians now recommend a “drug holiday” after several years of treatment. The general guideline is to consider a break of two to three years after five or more years of use, balancing the residual fracture protection that persists after stopping against the risk of the rare adverse events that accumulate with longer exposure.²¹

There is no one-size-fits-all answer for how long a holiday should last or when to restart. The recommendation is based on extensions of the original pivotal trials and on surrogate marker studies showing that bone density and turnover markers remain favorable for a period after discontinuation. Individual factors like fracture history, current bone density, age, and whether you are on other medications all play into the decision.²² Someone with a history of vertebral fractures and very low bone density may not be a good candidate for any holiday, while someone whose density has stabilized and who has no fracture history may safely pause for several years.

How Alendronate Compares to Alternatives

Alendronate is typically the first drug prescribed for osteoporosis, largely because it has the longest track record, the broadest evidence base, and the lowest cost. But it is not always the best choice for every patient, and the landscape of osteoporosis drugs has expanded considerably.

Among bisphosphonates, alendronate and risedronate are the two most commonly compared oral options. In head-to-head trials, alendronate produced slightly larger gains in bone density and slightly bigger drops in bone turnover markers over two years, with no significant difference in gastrointestinal side effects.²³ In one large observational study, risedronate users had a higher rate of hip fracture compared to alendronate users over a three-year follow-up, though fracture rates at other sites were similar.²⁴ A network meta-analysis of bisphosphonates in men, however, found no significant differences between alendronate, risedronate, ibandronate, and zoledronic acid for either vertebral or nonvertebral fracture prevention.²⁵ The overall message: within the bisphosphonate class, differences in fracture outcomes are modest at best.

The more interesting comparisons are between alendronate and drugs that work by a completely different mechanism. Teriparatide, a synthetic fragment of parathyroid hormone, builds new bone rather than just slowing its loss. A systematic review of head-to-head trials found that teriparatide was more effective than alendronate at increasing spine and hip bone density, though alendronate performed better at the femoral neck specifically.²⁶ A broader network meta-analysis in men ranked teriparatide highest for spine density improvement and overall safety, alendronate strongest for femoral neck and total hip gains, and denosumab (another non-bisphosphonate) effective at all sites but carrying the most adverse events.²⁷

Emerging evidence also suggests that sequencing matters. Rather than starting with alendronate and switching to an anabolic drug later if needed, some researchers now argue that starting with an anabolic agent first, then consolidating gains with a bisphosphonate like alendronate, may produce better long-term outcomes.²⁸ This is a shift from the traditional approach of reserving anabolic drugs for patients who fail bisphosphonates, and it has not yet become standard practice everywhere. But for people with very high fracture risk, the sequence of drugs may matter as much as which drug is chosen.

Kidney Impairment and Prescribing Caution

The official product labeling for alendronate recommends against using it in patients with significant kidney impairment, generally defined as a creatinine clearance below 35 mL per minute. This is a reasonable precaution, since bisphosphonates are cleared by the kidneys and could theoretically accumulate to harmful levels. In practice, though, many older adults with osteoporosis have some degree of reduced kidney function, and several published analyses have found that alendronate was well tolerated and effective in patients with impaired renal function, with no increase in adverse effects compared to patients with normal kidneys.²⁹ That said, the evidence is limited, and most clinicians will monitor kidney function carefully if they do prescribe it in this population.

Use in Children With Brittle Bone Disease

One of the more striking off-label uses of alendronate is in children with osteogenesis imperfecta, a genetic condition that produces extremely fragile bones. Intravenous bisphosphonates, particularly pamidronate, are the standard treatment, but oral alendronate has been studied as a more accessible alternative. In one trial of children with the condition, a year of alendronate therapy cut the average fracture rate from nearly four fractures per year to essentially zero, while significantly improving bone density scores, reducing chronic pain, and improving mobility. These benefits were maintained over an additional two years of follow-up.³⁰ A separate study confirmed similar findings: fracture rates dropped sharply and bone density improved in every individual child treated.³¹

These results are encouraging, but treating children with a drug designed to suppress bone turnover raises its own concerns. Growing bones need active remodeling, and the long-term effects of embedding bisphosphonates in a child’s skeleton for decades are not fully understood. Most pediatric specialists still prefer intravenous bisphosphonates for moderate to severe osteogenesis imperfecta, but oral alendronate offers a practical option where infusion centers are not available or for milder cases.

Monitoring Whether the Drug Is Working

Unlike a blood pressure pill, where you can check your numbers the same week, alendronate’s effect on bone density takes a year or more to show up on a DXA scan. Bone turnover markers in the blood, which reflect how actively bone is being broken down and rebuilt, respond much faster. Markers of bone resorption typically drop within weeks of starting treatment, and a marker of bone formation follows shortly after.³² Some clinicians use these markers to check adherence and early response within the first three to six months, rather than waiting two years for a follow-up bone density scan. If the markers have not dropped, it may signal that the patient is not taking the drug correctly, often an absorption issue related to food timing.